SLC5A2 and urinary tract infection: The effects of SGLT2 inhibition on urinary tract infection (1·08, 1·02–1·15), serious urinary tract infection (1·07, 0·90–1·27), mycotic genital infections (3·57, 3·14–4·06), severe hypoglycaemia (0·89, 0·80–0·98), and bone fracture (1·07, 0·99–1·14) are shown in the appendix (appendix p 23).